Satellos Bioscience (TSX:MSCL) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Debt-to-Equity?

Satellos Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Satellos Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Satellos Bioscience's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$40.67 Mil. Satellos Bioscience's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Satellos Bioscience's Debt-to-Equity or its related term are showing as below:

TSX:MSCL' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.94 Med: -5.94 Max: -5.94
Current: 0.05

During the past 4 years, the highest Debt-to-Equity Ratio of Satellos Bioscience was -5.94. The lowest was -5.94. And the median was -5.94.

TSX:MSCL's Debt-to-Equity is ranked better than
73.9% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSX:MSCL: 0.05

Satellos Bioscience Debt-to-Equity Historical Data

The historical data trend for Satellos Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Debt-to-Equity Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-5.94

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									-	0.95	0.04	-	-

Competitive Comparison of Satellos Bioscience's Debt-to-Equity

For the Biotechnology subindustry, Satellos Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Satellos Bioscience's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's Debt-to-Equity falls into.

Satellos Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Satellos Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	40.674
	=	0.00

Satellos Bioscience's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	40.674
	=	0.00

Satellos Bioscience (TSX:MSCL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Satellos Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0IT:Germany

Address

65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines